Analytical Data
-
基因名
Claudin-4/CLDN4 Protein-VLP
- Application
-
别名
CLDN4; claudin 4; CPETR, CPETR1; claudin-4; Clostridium perfringens enterotoxin receptor 1; CPE R; hCPE R; WBSCR8; Williams Beuren syndrome chromosomal region 8 protein;
-
种属
Human
-
表达系统
HEK293
-
标签
Tag Free
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O14493
-
表达区间
M1-V209
-
蛋白长度
Full Length
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-4 (CLDN4) is a tight junction protein primarily found in epithelial tissues, playing a crucial role in maintaining cell polarity and regulating paracellular permeability. Its dysregulation is associated with various pathological conditions, including cancer, where it is overexpressed in several tumors, making it a potential target for cancer immunotherapy. Researchers have increasingly focused on developing recombinant proteins and virus-like particles (VLPs) that encapsulate CLDN4 to enhance immune responses, aiming to create effective vaccines or therapeutic agents. The presentation of CLDN4 on VLPs can mimic the natural structure and function of the protein, facilitating the induction of robust humoral and cellular immune responses. This approach not only provides a platform for therapeutic immunization but also holds promise for targeted delivery strategies in clinical applications. By employing CLDN4/VLP systems, scientists aim to establish innovative treatment modalities for cancers that exhibit CLDN4 overexpression. Understanding the interaction between the immune system and CLDN4 presented on VLPs could yield critical insights into designing effective immunotherapeutics or vaccines targeting various malignancies.
